Selected research
Market Structure
Global Anti-angiogenic Ophthalmic Agent Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Anti-angiogenic Ophthalmic Agent market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Anti-angiogenic Ophthalmic Agent is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Anti-angiogenic Ophthalmic Agent is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Anti-angiogenic Ophthalmic Agent is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Anti-angiogenic Ophthalmic Agent is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Anti-angiogenic Ophthalmic Agent include Sun Pharma, Johnson & Johnson, Novartis AG, Gilead Sciences, Inc., Pfizer, Daiichi Sankyo, Bayer AG, The Geuder Group, MORCHER GmbH and Shanghai Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Anti-angiogenic Ophthalmic Agent market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Anti-angiogenic Ophthalmic Agent and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Anti-angiogenic Ophthalmic Agent sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Anti-angiogenic Ophthalmic Agent market size, projected growth trends, production technologies, key applications, and end-use industries.
Anti-angiogenic Ophthalmic Agent Segment by Company
Sun Pharma
Johnson & Johnson
Novartis AG
Gilead Sciences, Inc.
Pfizer
Daiichi Sankyo
Bayer AG
The Geuder Group, MORCHER GmbH
Shanghai Pharmaceuticals
Santen Pharmaceutical Co., Ltd.
Regeneron Pharmaceuticals, Inc.
Otsuka Pharmaceutical Co. Ltd
Novamedika
Medicom Health care
Implant ophthalmic products GmbH
Genentech, Inc.
Eyetech Inc.
ERC Labs
Becton, Dickinson and Company
Allergan plc
Anti-angiogenic Ophthalmic Agent Segment by Type
Diabetic Retinopathy
Myopic Choroidal Neovascularization
Macular Edema
Macular Degeneration
Anti-angiogenic Ophthalmic Agent Segment by Application
Hospital Pharmacies
Online Pharmacies
Retail Pharmacies
Anti-angiogenic Ophthalmic Agent Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-angiogenic Ophthalmic Agent market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Anti-angiogenic Ophthalmic Agent and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-angiogenic Ophthalmic Agent.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Anti-angiogenic Ophthalmic Agent market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Anti-angiogenic Ophthalmic Agent manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Anti-angiogenic Ophthalmic Agent in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Anti-angiogenic Ophthalmic Agent in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
List of Tables
Table 1. Anti-angiogenic Ophthalmic Agent Industry Trends
Table 2. Anti-angiogenic Ophthalmic Agent Industry Drivers
Table 3. Anti-angiogenic Ophthalmic Agent Industry Opportunities and Challenges
Table 4. Anti-angiogenic Ophthalmic Agent Industry Restraints
Table 5. Global Anti-angiogenic Ophthalmic Agent Revenue by Manufacturers (US$ Million) & (2021-2026)
Table 6. Global Anti-angiogenic Ophthalmic Agent Revenue Market Share by Manufacturers (2021-2026)
Table 7. Global Anti-angiogenic Ophthalmic Agent Sales by Manufacturers (k units) & (2021-2026)
Table 8. Global Anti-angiogenic Ophthalmic Agent Sales Market Share by Manufacturers
Table 9. Global Anti-angiogenic Ophthalmic Agent Average Sales Price (US$/unit) of Manufacturers (2021-2026)
Table 10. Global Anti-angiogenic Ophthalmic Agent Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
Table 11. Global Anti-angiogenic Ophthalmic Agent Key Manufacturers Manufacturing Sites & Headquarters
Table 12. Global Anti-angiogenic Ophthalmic Agent Manufacturers, Product Type & Application
Table 13. Global Anti-angiogenic Ophthalmic Agent Manufacturers Establishment Date
Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 15. Global Anti-angiogenic Ophthalmic Agent by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025)
Table 16. Major Manufacturers of Diabetic Retinopathy
Table 17. Major Manufacturers of Myopic Choroidal Neovascularization
Table 18. Major Manufacturers of Macular Edema
Table 19. Major Manufacturers of Macular Degeneration
Table 20. Global Anti-angiogenic Ophthalmic Agent Sales by Type 2021 VS 2025 VS 2032 (k units)
Table 21. Global Anti-angiogenic Ophthalmic Agent Sales by Type (2021-2026) & (k units)
Table 22. Global Anti-angiogenic Ophthalmic Agent Sales by Type (2027-2032) & (k units)
Table 23. Global Anti-angiogenic Ophthalmic Agent Sales Market Share by Type (2021-2026)
Table 24. Global Anti-angiogenic Ophthalmic Agent Sales Market Share by Type (2027-2032)
Table 25. Global Anti-angiogenic Ophthalmic Agent Revenue by Type 2021 VS 2025 VS 2032 (k units)
Table 26. Global Anti-angiogenic Ophthalmic Agent Revenue by Type (2021-2026) & (k units)
Table 27. Global Anti-angiogenic Ophthalmic Agent Revenue by Type (2027-2032) & (k units)
Table 28. Global Anti-angiogenic Ophthalmic Agent Revenue Market Share by Type (2021-2026)
Table 29. Global Anti-angiogenic Ophthalmic Agent Revenue Market Share by Type (2027-2032)
Table 30. Major Manufacturers of Hospital Pharmacies
Table 31. Major Manufacturers of Online Pharmacies
Table 32. Major Manufacturers of Retail Pharmacies
Table 33. Global Anti-angiogenic Ophthalmic Agent Sales by Application 2021 VS 2025 VS 2032 (k units)
Table 34. Global Anti-angiogenic Ophthalmic Agent Sales by Application (2021-2026) & (k units)
Table 35. Global Anti-angiogenic Ophthalmic Agent Sales by Application (2027-2032) & (k units)
Table 36. Global Anti-angiogenic Ophthalmic Agent Sales Market Share by Application (2021-2026)
Table 37. Global Anti-angiogenic Ophthalmic Agent Sales Market Share by Application (2027-2032)
Table 38. Global Anti-angiogenic Ophthalmic Agent Revenue by Application 2021 VS 2025 VS 2032 (k units)
Table 39. Global Anti-angiogenic Ophthalmic Agent Revenue by Application (2021-2026) & (k units)
Table 40. Global Anti-angiogenic Ophthalmic Agent Revenue by Application (2027-2032) & (k units)
Table 41. Global Anti-angiogenic Ophthalmic Agent Revenue Market Share by Application (2021-2026)
Table 42. Global Anti-angiogenic Ophthalmic Agent Revenue Market Share by Application (2027-2032)
Table 43. Global Anti-angiogenic Ophthalmic Agent Sales by Region: 2021 VS 2025 VS 2032 (k units)
Table 44. Global Anti-angiogenic Ophthalmic Agent Sales by Region (2021-2026) & (k units)
Table 45. Global Anti-angiogenic Ophthalmic Agent Sales Market Share by Region (2021-2026)
Table 46. Global Anti-angiogenic Ophthalmic Agent Sales Forecasted by Region (2027-2032) & (k units)
Table 47. Global Anti-angiogenic Ophthalmic Agent Sales Forecasted Market Share by Region (2027-2032)
Table 48. North America Anti-angiogenic Ophthalmic Agent Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units)
Table 49. North America Anti-angiogenic Ophthalmic Agent Sales by Country (2021-2026) & (k units)
Table 50. North America Anti-angiogenic Ophthalmic Agent Sales by Country (2027-2032) & (k units)
Table 51. Europe Anti-angiogenic Ophthalmic Agent Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units)
Table 52. Europe Anti-angiogenic Ophthalmic Agent Sales by Country (2021-2026) & (k units)
Table 53. Europe Anti-angiogenic Ophthalmic Agent Sales by Country (2027-2032) & (k units)
Table 54. Asia Pacific Anti-angiogenic Ophthalmic Agent Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units)
Table 55. Asia Pacific Anti-angiogenic Ophthalmic Agent Sales by Country (2021-2026) & (k units)
Table 56. Asia Pacific Anti-angiogenic Ophthalmic Agent Sales by Country (2027-2032) & (k units)
Table 57. South America, Middle East and Africa Anti-angiogenic Ophthalmic Agent Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units)
Table 58. South America, Middle East and Africa Anti-angiogenic Ophthalmic Agent Sales by Country (2021-2026) & (k units)
Table 59. South America, Middle East and Africa Anti-angiogenic Ophthalmic Agent Sales by Country (2027-2032) & (k units)
Table 60. Global Anti-angiogenic Ophthalmic Agent Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million)
Table 61. Global Anti-angiogenic Ophthalmic Agent Revenue by Region (2021-2026) & (US$ Million)
Table 62. Global Anti-angiogenic Ophthalmic Agent Revenue by Region (2027-2032) & (US$ Million)
Table 63. Global Anti-angiogenic Ophthalmic Agent Revenue Market Share by Region (2021-2026)
Table 64. Global Anti-angiogenic Ophthalmic Agent Revenue Market Share by Region (2027-2032)
Table 65. Sun Pharma Company Information
Table 66. Sun Pharma Business Overview
Table 67. Sun Pharma Anti-angiogenic Ophthalmic Agent Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 68. Sun Pharma Anti-angiogenic Ophthalmic Agent Product Portfolio
Table 69. Sun Pharma Recent Development
Table 70. Johnson & Johnson Company Information
Table 71. Johnson & Johnson Business Overview
Table 72. Johnson & Johnson Anti-angiogenic Ophthalmic Agent Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 73. Johnson & Johnson Anti-angiogenic Ophthalmic Agent Product Portfolio
Table 74. Johnson & Johnson Recent Development
Table 75. Novartis AG Company Information
Table 76. Novartis AG Business Overview
Table 77. Novartis AG Anti-angiogenic Ophthalmic Agent Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 78. Novartis AG Anti-angiogenic Ophthalmic Agent Product Portfolio
Table 79. Novartis AG Recent Development
Table 80. Gilead Sciences, Inc. Company Information
Table 81. Gilead Sciences, Inc. Business Overview
Table 82. Gilead Sciences, Inc. Anti-angiogenic Ophthalmic Agent Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 83. Gilead Sciences, Inc. Anti-angiogenic Ophthalmic Agent Product Portfolio
Table 84. Gilead Sciences, Inc. Recent Development
Table 85. Pfizer Company Information
Table 86. Pfizer Business Overview
Table 87. Pfizer Anti-angiogenic Ophthalmic Agent Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 88. Pfizer Anti-angiogenic Ophthalmic Agent Product Portfolio
Table 89. Pfizer Recent Development
Table 90. Daiichi Sankyo Company Information
Table 91. Daiichi Sankyo Business Overview
Table 92. Daiichi Sankyo Anti-angiogenic Ophthalmic Agent Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 93. Daiichi Sankyo Anti-angiogenic Ophthalmic Agent Product Portfolio
Table 94. Daiichi Sankyo Recent Development
Table 95. Bayer AG Company Information
Table 96. Bayer AG Business Overview
Table 97. Bayer AG Anti-angiogenic Ophthalmic Agent Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 98. Bayer AG Anti-angiogenic Ophthalmic Agent Product Portfolio
Table 99. Bayer AG Recent Development
Table 100. The Geuder Group, MORCHER GmbH Company Information
Table 101. The Geuder Group, MORCHER GmbH Business Overview
Table 102. The Geuder Group, MORCHER GmbH Anti-angiogenic Ophthalmic Agent Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 103. The Geuder Group, MORCHER GmbH Anti-angiogenic Ophthalmic Agent Product Portfolio
Table 104. The Geuder Group, MORCHER GmbH Recent Development
Table 105. Shanghai Pharmaceuticals Company Information
Table 106. Shanghai Pharmaceuticals Business Overview
Table 107. Shanghai Pharmaceuticals Anti-angiogenic Ophthalmic Agent Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 108. Shanghai Pharmaceuticals Anti-angiogenic Ophthalmic Agent Product Portfolio
Table 109. Shanghai Pharmaceuticals Recent Development
Table 110. Santen Pharmaceutical Co., Ltd. Company Information
Table 111. Santen Pharmaceutical Co., Ltd. Business Overview
Table 112. Santen Pharmaceutical Co., Ltd. Anti-angiogenic Ophthalmic Agent Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 113. Santen Pharmaceutical Co., Ltd. Anti-angiogenic Ophthalmic Agent Product Portfolio
Table 114. Santen Pharmaceutical Co., Ltd. Recent Development
Table 115. Regeneron Pharmaceuticals, Inc. Company Information
Table 116. Regeneron Pharmaceuticals, Inc. Business Overview
Table 117. Regeneron Pharmaceuticals, Inc. Anti-angiogenic Ophthalmic Agent Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 118. Regeneron Pharmaceuticals, Inc. Anti-angiogenic Ophthalmic Agent Product Portfolio
Table 119. Regeneron Pharmaceuticals, Inc. Recent Development
Table 120. Otsuka Pharmaceutical Co. Ltd Company Information
Table 121. Otsuka Pharmaceutical Co. Ltd Business Overview
Table 122. Otsuka Pharmaceutical Co. Ltd Anti-angiogenic Ophthalmic Agent Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 123. Otsuka Pharmaceutical Co. Ltd Anti-angiogenic Ophthalmic Agent Product Portfolio
Table 124. Otsuka Pharmaceutical Co. Ltd Recent Development
Table 125. Novamedika Company Information
Table 126. Novamedika Business Overview
Table 127. Novamedika Anti-angiogenic Ophthalmic Agent Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 128. Novamedika Anti-angiogenic Ophthalmic Agent Product Portfolio
Table 129. Novamedika Recent Development
Table 130. Medicom Health care Company Information
Table 131. Medicom Health care Business Overview
Table 132. Medicom Health care Anti-angiogenic Ophthalmic Agent Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 133. Medicom Health care Anti-angiogenic Ophthalmic Agent Product Portfolio
Table 134. Medicom Health care Recent Development
Table 135. Implant ophthalmic products GmbH Company Information
Table 136. Implant ophthalmic products GmbH Business Overview
Table 137. Implant ophthalmic products GmbH Anti-angiogenic Ophthalmic Agent Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 138. Implant ophthalmic products GmbH Anti-angiogenic Ophthalmic Agent Product Portfolio
Table 139. Implant ophthalmic products GmbH Recent Development
Table 140. Genentech, Inc. Company Information
Table 141. Genentech, Inc. Business Overview
Table 142. Genentech, Inc. Anti-angiogenic Ophthalmic Agent Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 143. Genentech, Inc. Anti-angiogenic Ophthalmic Agent Product Portfolio
Table 144. Genentech, Inc. Recent Development
Table 145. Eyetech Inc. Company Information
Table 146. Eyetech Inc. Business Overview
Table 147. Eyetech Inc. Anti-angiogenic Ophthalmic Agent Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 148. Eyetech Inc. Anti-angiogenic Ophthalmic Agent Product Portfolio
Table 149. Eyetech Inc. Recent Development
Table 150. ERC Labs Company Information
Table 151. ERC Labs Business Overview
Table 152. ERC Labs Anti-angiogenic Ophthalmic Agent Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 153. ERC Labs Anti-angiogenic Ophthalmic Agent Product Portfolio
Table 154. ERC Labs Recent Development
Table 155. Becton, Dickinson and Company Company Information
Table 156. Becton, Dickinson and Company Business Overview
Table 157. Becton, Dickinson and Company Anti-angiogenic Ophthalmic Agent Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 158. Becton, Dickinson and Company Anti-angiogenic Ophthalmic Agent Product Portfolio
Table 159. Becton, Dickinson and Company Recent Development
Table 160. Allergan plc Company Information
Table 161. Allergan plc Business Overview
Table 162. Allergan plc Anti-angiogenic Ophthalmic Agent Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 163. Allergan plc Anti-angiogenic Ophthalmic Agent Product Portfolio
Table 164. Allergan plc Recent Development
Table 165. Key Raw Materials
Table 166. Raw Materials Key Suppliers
Table 167. Anti-angiogenic Ophthalmic Agent Distributors List
Table 168. Anti-angiogenic Ophthalmic Agent Customers List
Table 169. Research Programs/Design for This Report
Table 170. Authors List of This Report
Table 171. Secondary Sources
Table 172. Primary Sources
List of Figures
Figure 1. Anti-angiogenic Ophthalmic Agent Product Image
Figure 2. Global Anti-angiogenic Ophthalmic Agent Market Size (US$ Million), 2021 VS 2025 VS 2032
Figure 3. Global Anti-angiogenic Ophthalmic Agent Market Size (2021-2032) & (US$ Million)
Figure 4. Global Anti-angiogenic Ophthalmic Agent Sales (2021-2032) & (k units)
Figure 5. Global Anti-angiogenic Ophthalmic Agent Average Price (US$/unit) & (2021-2032)
Figure 6. Global Top 5 and 10 Anti-angiogenic Ophthalmic Agent Players Market Share by Revenue in 2025
Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
Figure 8. Diabetic Retinopathy Image
Figure 9. Myopic Choroidal Neovascularization Image
Figure 10. Macular Edema Image
Figure 11. Macular Degeneration Image
Figure 12. Global Anti-angiogenic Ophthalmic Agent Sales by Type (2021 VS 2025 VS 2032) & (k units)
Figure 13. Global Anti-angiogenic Ophthalmic Agent Sales Market Share 2021 VS 2025 VS 2032
Figure 14. Global Anti-angiogenic Ophthalmic Agent Sales Market Share by Type (2021-2032)
Figure 15. Global Anti-angiogenic Ophthalmic Agent Revenue by Type (2021 VS 2025 VS 2032) & (k units)
Figure 16. Global Anti-angiogenic Ophthalmic Agent Revenue Market Share 2021 VS 2025 VS 2032
Figure 17. Global Anti-angiogenic Ophthalmic Agent Revenue Market Share by Type (2021-2032)
Figure 18. Hospital Pharmacies Image
Figure 19. Online Pharmacies Image
Figure 20. Retail Pharmacies Image
Figure 21. Global Anti-angiogenic Ophthalmic Agent Sales by Application (2021 VS 2025 VS 2032) & (k units)
Figure 22. Global Anti-angiogenic Ophthalmic Agent Sales Market Share 2021 VS 2025 VS 2032
Figure 23. Global Anti-angiogenic Ophthalmic Agent Sales Market Share by Application (2021-2032)
Figure 24. Global Anti-angiogenic Ophthalmic Agent Revenue by Application (2021 VS 2025 VS 2032) & (k units)
Figure 25. Global Anti-angiogenic Ophthalmic Agent Revenue Market Share 2021 VS 2025 VS 2032
Figure 26. Global Anti-angiogenic Ophthalmic Agent Revenue Market Share by Application (2021-2032)
Figure 27. North America Anti-angiogenic Ophthalmic Agent Sales and Growth Rate (2021-2032) & (k units)
Figure 28. North America Anti-angiogenic Ophthalmic Agent Sales Market Share by Country (2021-2032)
Figure 29. U.S. Anti-angiogenic Ophthalmic Agent Sales and Growth Rate (2021-2032) & (k units)
Figure 30. Canada Anti-angiogenic Ophthalmic Agent Sales and Growth Rate (2021-2032) & (k units)
Figure 31. Mexico Anti-angiogenic Ophthalmic Agent Sales and Growth Rate (2021-2032) & (k units)
Figure 32. Europe Anti-angiogenic Ophthalmic Agent Sales and Growth Rate (2021-2032) & (k units)
Figure 33. Europe Anti-angiogenic Ophthalmic Agent Sales Market Share by Country (2021-2032)
Figure 34. Germany Anti-angiogenic Ophthalmic Agent Sales and Growth Rate (2021-2032) & (k units)
Figure 35. France Anti-angiogenic Ophthalmic Agent Sales and Growth Rate (2021-2032) & (k units)
Figure 36. U.K. Anti-angiogenic Ophthalmic Agent Sales and Growth Rate (2021-2032) & (k units)
Figure 37. Italy Anti-angiogenic Ophthalmic Agent Sales and Growth Rate (2021-2032) & (k units)
Figure 38. Netherlands Anti-angiogenic Ophthalmic Agent Sales and Growth Rate (2021-2032) & (k units)
Figure 39. Asia Pacific Anti-angiogenic Ophthalmic Agent Sales and Growth Rate (2021-2032) & (k units)
Figure 40. Asia Pacific Anti-angiogenic Ophthalmic Agent Sales Market Share by Country (2021-2032)
Figure 41. China Anti-angiogenic Ophthalmic Agent Sales and Growth Rate (2021-2032) & (k units)
Figure 42. Japan Anti-angiogenic Ophthalmic Agent Sales and Growth Rate (2021-2032) & (k units)
Figure 43. South Korea Anti-angiogenic Ophthalmic Agent Sales and Growth Rate (2021-2032) & (k units)
Figure 44. Southeast Asia Anti-angiogenic Ophthalmic Agent Sales and Growth Rate (2021-2032) & (k units)
Figure 45. India Anti-angiogenic Ophthalmic Agent Sales and Growth Rate (2021-2032) & (k units)
Figure 46. Australia Anti-angiogenic Ophthalmic Agent Sales and Growth Rate (2021-2032) & (k units)
Figure 47. South America, Middle East and Africa Anti-angiogenic Ophthalmic Agent Sales and Growth Rate (2021-2032) & (k units)
Figure 48. South America, Middle East and Africa Anti-angiogenic Ophthalmic Agent Sales Market Share by Country (2021-2032)
Figure 49. Brazil Anti-angiogenic Ophthalmic Agent Sales and Growth Rate (2021-2032) & (k units)
Figure 50. South Africa Anti-angiogenic Ophthalmic Agent Sales and Growth Rate (2021-2032) & (k units)
Figure 51. Saudi Arabia Anti-angiogenic Ophthalmic Agent Sales and Growth Rate (2021-2032) & (k units)
Figure 52. Turkey Anti-angiogenic Ophthalmic Agent Sales and Growth Rate (2021-2032) & (k units)
Figure 53. Argentina Anti-angiogenic Ophthalmic Agent Sales and Growth Rate (2021-2032) & (k units)
Figure 54. UAE Anti-angiogenic Ophthalmic Agent Sales and Growth Rate (2021-2032) & (k units)
Figure 55. Egypt Anti-angiogenic Ophthalmic Agent Sales and Growth Rate (2021-2032) & (k units)
Figure 56. Chile Anti-angiogenic Ophthalmic Agent Sales and Growth Rate (2021-2032) & (k units)
Figure 57. Global Anti-angiogenic Ophthalmic Agent Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million)
Figure 58. Global Anti-angiogenic Ophthalmic Agent Revenue Market Share by Region in Percentage: 2025 Versus 2032
Figure 59. North America Anti-angiogenic Ophthalmic Agent Revenue (2021-2032) & (US$ Million)
Figure 60. North America Anti-angiogenic Ophthalmic Agent Revenue Share by Country: 2021 VS 2025 VS 2032
Figure 61. Europe Anti-angiogenic Ophthalmic Agent Revenue (2021-2032) & (US$ Million)
Figure 62. Europe Anti-angiogenic Ophthalmic Agent Revenue Share by Country: 2021 VS 2025 VS 2032
Figure 63. Asia-Pacific Anti-angiogenic Ophthalmic Agent Revenue (2021-2032) & (US$ Million)
Figure 64. Asia-Pacific Anti-angiogenic Ophthalmic Agent Revenue Share by Country: 2021 VS 2025 VS 2032
Figure 65. South America, Middle East and Africa Anti-angiogenic Ophthalmic Agent Revenue (2021-2032) & (US$ Million)
Figure 66. South America, Middle East and Africa Anti-angiogenic Ophthalmic Agent Revenue Share by Country: 2021 VS 2025 VS 2032
Figure 67. Anti-angiogenic Ophthalmic Agent Value Chain
Figure 68. Manufacturing Cost Structure
Figure 69. Anti-angiogenic Ophthalmic Agent Production Mode & Process
Figure 70. Direct Comparison with Distribution Share
Figure 71. Distributors Profiles
Figure 72. Years Considered
Figure 73. Research Process
Figure 74. Key Executives Interviewed
Scope & coverage.
Types
- Diabetic Retinopathy
- Myopic Choroidal Neovascularization
- Macular Edema
- Macular Degeneration
Applications
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
Companies covered
- Sun Pharma
- Johnson & Johnson
- Novartis AG
- Gilead Sciences, Inc.
- Pfizer
- Daiichi Sankyo
- Bayer AG
- The Geuder Group, MORCHER GmbH
- Shanghai Pharmaceuticals
- Santen Pharmaceutical Co., Ltd.
- Regeneron Pharmaceuticals, Inc.
- Otsuka Pharmaceutical Co. Ltd
- Novamedika
- Medicom Health care
- Implant ophthalmic products GmbH
- Genentech, Inc.
- Eyetech Inc.
- ERC Labs
- Becton, Dickinson and Company
- Allergan plc
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Anti-angiogenic Ophthalmic Agent Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Anti-angiogenic Ophthalmic Agent Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Anti-angiogenic Ophthalmic Agent Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Anti-angiogenic Ophthalmic Agent Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Anti-angiogenic Ophthalmic Agent Market Dynamics
- 2.1 Anti-angiogenic Ophthalmic Agent Industry Trends
- 2.2 Anti-angiogenic Ophthalmic Agent Industry Drivers
- 2.3 Anti-angiogenic Ophthalmic Agent Industry Opportunities and Challenges
- 2.4 Anti-angiogenic Ophthalmic Agent Industry Restraints
3 Anti-angiogenic Ophthalmic Agent Market by Manufacturers
- 3.1 Global Anti-angiogenic Ophthalmic Agent Revenue by Manufacturers (2021-2026)
- 3.2 Global Anti-angiogenic Ophthalmic Agent Sales by Manufacturers (2021-2026)
- 3.3 Global Anti-angiogenic Ophthalmic Agent Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Anti-angiogenic Ophthalmic Agent Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Anti-angiogenic Ophthalmic Agent Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Anti-angiogenic Ophthalmic Agent Manufacturers, Product Type & Application
- 3.7 Global Anti-angiogenic Ophthalmic Agent Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Anti-angiogenic Ophthalmic Agent Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Anti-angiogenic Ophthalmic Agent Players Market Share by Revenue in 2025
- 3.8.3 2025 Anti-angiogenic Ophthalmic Agent Tier 1, Tier 2, and Tier 3
4 Anti-angiogenic Ophthalmic Agent Market by Type
- 4.1 Anti-angiogenic Ophthalmic Agent Type Introduction
- 4.1.1 Diabetic Retinopathy
- 4.1.2 Myopic Choroidal Neovascularization
- 4.1.3 Macular Edema
- 4.1.4 Macular Degeneration
- 4.2 Global Anti-angiogenic Ophthalmic Agent Sales by Type
- 4.2.1 Global Anti-angiogenic Ophthalmic Agent Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Anti-angiogenic Ophthalmic Agent Sales by Type (2021-2032)
- 4.2.3 Global Anti-angiogenic Ophthalmic Agent Sales Market Share by Type (2021-2032)
- 4.3 Global Anti-angiogenic Ophthalmic Agent Revenue by Type
- 4.3.1 Global Anti-angiogenic Ophthalmic Agent Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Anti-angiogenic Ophthalmic Agent Revenue by Type (2021-2032)
- 4.3.3 Global Anti-angiogenic Ophthalmic Agent Revenue Market Share by Type (2021-2032)
5 Anti-angiogenic Ophthalmic Agent Market by Application
- 5.1 Anti-angiogenic Ophthalmic Agent Application Introduction
- 5.1.1 Hospital Pharmacies
- 5.1.2 Online Pharmacies
- 5.1.3 Retail Pharmacies
- 5.2 Global Anti-angiogenic Ophthalmic Agent Sales by Application
- 5.2.1 Global Anti-angiogenic Ophthalmic Agent Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Anti-angiogenic Ophthalmic Agent Sales by Application (2021-2032)
- 5.2.3 Global Anti-angiogenic Ophthalmic Agent Sales Market Share by Application (2021-2032)
- 5.3 Global Anti-angiogenic Ophthalmic Agent Revenue by Application
- 5.3.1 Global Anti-angiogenic Ophthalmic Agent Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Anti-angiogenic Ophthalmic Agent Revenue by Application (2021-2032)
- 5.3.3 Global Anti-angiogenic Ophthalmic Agent Revenue Market Share by Application (2021-2032)
6 Global Anti-angiogenic Ophthalmic Agent Sales by Region
- 6.1 Global Anti-angiogenic Ophthalmic Agent Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Anti-angiogenic Ophthalmic Agent Sales by Region (2021-2032)
- 6.2.1 Global Anti-angiogenic Ophthalmic Agent Sales by Region (2021-2026)
- 6.2.2 Global Anti-angiogenic Ophthalmic Agent Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Anti-angiogenic Ophthalmic Agent Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Anti-angiogenic Ophthalmic Agent Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Anti-angiogenic Ophthalmic Agent Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Anti-angiogenic Ophthalmic Agent Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Anti-angiogenic Ophthalmic Agent Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Anti-angiogenic Ophthalmic Agent Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Anti-angiogenic Ophthalmic Agent Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Anti-angiogenic Ophthalmic Agent Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Anti-angiogenic Ophthalmic Agent Revenue by Region
- 7.1 Global Anti-angiogenic Ophthalmic Agent Revenue by Region
- 7.1.1 Global Anti-angiogenic Ophthalmic Agent Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Anti-angiogenic Ophthalmic Agent Revenue by Region (2021-2026)
- 7.1.3 Global Anti-angiogenic Ophthalmic Agent Revenue by Region (2027-2032)
- 7.1.4 Global Anti-angiogenic Ophthalmic Agent Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Anti-angiogenic Ophthalmic Agent Revenue (2021-2032)
- 7.2.2 North America Anti-angiogenic Ophthalmic Agent Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Anti-angiogenic Ophthalmic Agent Revenue (2021-2032)
- 7.3.2 Europe Anti-angiogenic Ophthalmic Agent Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Anti-angiogenic Ophthalmic Agent Revenue (2021-2032)
- 7.4.2 Asia-Pacific Anti-angiogenic Ophthalmic Agent Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Anti-angiogenic Ophthalmic Agent Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Anti-angiogenic Ophthalmic Agent Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Sun Pharma
- 8.1.1 Sun Pharma Company Information
- 8.1.2 Sun Pharma Business Overview
- 8.1.3 Sun Pharma Anti-angiogenic Ophthalmic Agent Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Sun Pharma Anti-angiogenic Ophthalmic Agent Product Portfolio
- 8.1.5 Sun Pharma Recent Developments
- 8.2 Johnson & Johnson
- 8.2.1 Johnson & Johnson Company Information
- 8.2.2 Johnson & Johnson Business Overview
- 8.2.3 Johnson & Johnson Anti-angiogenic Ophthalmic Agent Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Johnson & Johnson Anti-angiogenic Ophthalmic Agent Product Portfolio
- 8.2.5 Johnson & Johnson Recent Developments
- 8.3 Novartis AG
- 8.3.1 Novartis AG Company Information
- 8.3.2 Novartis AG Business Overview
- 8.3.3 Novartis AG Anti-angiogenic Ophthalmic Agent Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Novartis AG Anti-angiogenic Ophthalmic Agent Product Portfolio
- 8.3.5 Novartis AG Recent Developments
- 8.4 Gilead Sciences, Inc.
- 8.4.1 Gilead Sciences, Inc. Company Information
- 8.4.2 Gilead Sciences, Inc. Business Overview
- 8.4.3 Gilead Sciences, Inc. Anti-angiogenic Ophthalmic Agent Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Gilead Sciences, Inc. Anti-angiogenic Ophthalmic Agent Product Portfolio
- 8.4.5 Gilead Sciences, Inc. Recent Developments
- 8.5 Pfizer
- 8.5.1 Pfizer Company Information
- 8.5.2 Pfizer Business Overview
- 8.5.3 Pfizer Anti-angiogenic Ophthalmic Agent Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Pfizer Anti-angiogenic Ophthalmic Agent Product Portfolio
- 8.5.5 Pfizer Recent Developments
- 8.6 Daiichi Sankyo
- 8.6.1 Daiichi Sankyo Company Information
- 8.6.2 Daiichi Sankyo Business Overview
- 8.6.3 Daiichi Sankyo Anti-angiogenic Ophthalmic Agent Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Daiichi Sankyo Anti-angiogenic Ophthalmic Agent Product Portfolio
- 8.6.5 Daiichi Sankyo Recent Developments
- 8.7 Bayer AG
- 8.7.1 Bayer AG Company Information
- 8.7.2 Bayer AG Business Overview
- 8.7.3 Bayer AG Anti-angiogenic Ophthalmic Agent Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 Bayer AG Anti-angiogenic Ophthalmic Agent Product Portfolio
- 8.7.5 Bayer AG Recent Developments
- 8.8 The Geuder Group, MORCHER GmbH
- 8.8.1 The Geuder Group, MORCHER GmbH Company Information
- 8.8.2 The Geuder Group, MORCHER GmbH Business Overview
- 8.8.3 The Geuder Group, MORCHER GmbH Anti-angiogenic Ophthalmic Agent Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 The Geuder Group, MORCHER GmbH Anti-angiogenic Ophthalmic Agent Product Portfolio
- 8.8.5 The Geuder Group, MORCHER GmbH Recent Developments
- 8.9 Shanghai Pharmaceuticals
- 8.9.1 Shanghai Pharmaceuticals Company Information
- 8.9.2 Shanghai Pharmaceuticals Business Overview
- 8.9.3 Shanghai Pharmaceuticals Anti-angiogenic Ophthalmic Agent Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.9.4 Shanghai Pharmaceuticals Anti-angiogenic Ophthalmic Agent Product Portfolio
- 8.9.5 Shanghai Pharmaceuticals Recent Developments
- 8.10 Santen Pharmaceutical Co., Ltd.
- 8.10.1 Santen Pharmaceutical Co., Ltd. Company Information
- 8.10.2 Santen Pharmaceutical Co., Ltd. Business Overview
- 8.10.3 Santen Pharmaceutical Co., Ltd. Anti-angiogenic Ophthalmic Agent Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.10.4 Santen Pharmaceutical Co., Ltd. Anti-angiogenic Ophthalmic Agent Product Portfolio
- 8.10.5 Santen Pharmaceutical Co., Ltd. Recent Developments
- 8.11 Regeneron Pharmaceuticals, Inc.
- 8.11.1 Regeneron Pharmaceuticals, Inc. Company Information
- 8.11.2 Regeneron Pharmaceuticals, Inc. Business Overview
- 8.11.3 Regeneron Pharmaceuticals, Inc. Anti-angiogenic Ophthalmic Agent Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.11.4 Regeneron Pharmaceuticals, Inc. Anti-angiogenic Ophthalmic Agent Product Portfolio
- 8.11.5 Regeneron Pharmaceuticals, Inc. Recent Developments
- 8.12 Otsuka Pharmaceutical Co. Ltd
- 8.12.1 Otsuka Pharmaceutical Co. Ltd Company Information
- 8.12.2 Otsuka Pharmaceutical Co. Ltd Business Overview
- 8.12.3 Otsuka Pharmaceutical Co. Ltd Anti-angiogenic Ophthalmic Agent Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.12.4 Otsuka Pharmaceutical Co. Ltd Anti-angiogenic Ophthalmic Agent Product Portfolio
- 8.12.5 Otsuka Pharmaceutical Co. Ltd Recent Developments
- 8.13 Novamedika
- 8.13.1 Novamedika Company Information
- 8.13.2 Novamedika Business Overview
- 8.13.3 Novamedika Anti-angiogenic Ophthalmic Agent Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.13.4 Novamedika Anti-angiogenic Ophthalmic Agent Product Portfolio
- 8.13.5 Novamedika Recent Developments
- 8.14 Medicom Health care
- 8.14.1 Medicom Health care Company Information
- 8.14.2 Medicom Health care Business Overview
- 8.14.3 Medicom Health care Anti-angiogenic Ophthalmic Agent Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.14.4 Medicom Health care Anti-angiogenic Ophthalmic Agent Product Portfolio
- 8.14.5 Medicom Health care Recent Developments
- 8.15 Implant ophthalmic products GmbH
- 8.15.1 Implant ophthalmic products GmbH Company Information
- 8.15.2 Implant ophthalmic products GmbH Business Overview
- 8.15.3 Implant ophthalmic products GmbH Anti-angiogenic Ophthalmic Agent Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.15.4 Implant ophthalmic products GmbH Anti-angiogenic Ophthalmic Agent Product Portfolio
- 8.15.5 Implant ophthalmic products GmbH Recent Developments
- 8.16 Genentech, Inc.
- 8.16.1 Genentech, Inc. Company Information
- 8.16.2 Genentech, Inc. Business Overview
- 8.16.3 Genentech, Inc. Anti-angiogenic Ophthalmic Agent Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.16.4 Genentech, Inc. Anti-angiogenic Ophthalmic Agent Product Portfolio
- 8.16.5 Genentech, Inc. Recent Developments
- 8.17 Eyetech Inc.
- 8.17.1 Eyetech Inc. Company Information
- 8.17.2 Eyetech Inc. Business Overview
- 8.17.3 Eyetech Inc. Anti-angiogenic Ophthalmic Agent Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.17.4 Eyetech Inc. Anti-angiogenic Ophthalmic Agent Product Portfolio
- 8.17.5 Eyetech Inc. Recent Developments
- 8.18 ERC Labs
- 8.18.1 ERC Labs Company Information
- 8.18.2 ERC Labs Business Overview
- 8.18.3 ERC Labs Anti-angiogenic Ophthalmic Agent Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.18.4 ERC Labs Anti-angiogenic Ophthalmic Agent Product Portfolio
- 8.18.5 ERC Labs Recent Developments
- 8.19 Becton, Dickinson and Company
- 8.19.1 Becton, Dickinson and Company Company Information
- 8.19.2 Becton, Dickinson and Company Business Overview
- 8.19.3 Becton, Dickinson and Company Anti-angiogenic Ophthalmic Agent Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.19.4 Becton, Dickinson and Company Anti-angiogenic Ophthalmic Agent Product Portfolio
- 8.19.5 Becton, Dickinson and Company Recent Developments
- 8.20 Allergan plc
- 8.20.1 Allergan plc Company Information
- 8.20.2 Allergan plc Business Overview
- 8.20.3 Allergan plc Anti-angiogenic Ophthalmic Agent Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.20.4 Allergan plc Anti-angiogenic Ophthalmic Agent Product Portfolio
- 8.20.5 Allergan plc Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Anti-angiogenic Ophthalmic Agent Value Chain Analysis
- 9.1.1 Anti-angiogenic Ophthalmic Agent Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Anti-angiogenic Ophthalmic Agent Production Mode & Process
- 9.2 Anti-angiogenic Ophthalmic Agent Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Anti-angiogenic Ophthalmic Agent Distributors
- 9.2.3 Anti-angiogenic Ophthalmic Agent Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
$3,950USD
Buy nowPDF by email within 3–5 working days after payment confirmation.
Talk to an analyst